Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-30
2009-11-17
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07618998
ABSTRACT:
An isoflavone derivative is provided. The isoxazole derivative has following formula:wherein R1and R2, independently, include C1-C12alkyl optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy, and R3includes hydrogen, hydroxy or C1-C12alkoxy optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy. The invention also provides a pharmaceutical composition for treatment of osteoporosis including an isoflavone derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 4501755 (1985-02-01), Wu
patent: 4668804 (1987-05-01), Wu
patent: 5247102 (1993-09-01), Kallay et al.
patent: 5973169 (1999-10-01), Ferrari
patent: 2006/0100238 (2006-05-01), Kelly et al.
patent: 1475488 (2004-02-01), None
patent: 1603318 (2005-04-01), None
patent: 0136569 (1985-04-01), None
patent: 0941992 (1999-09-01), None
patent: 0941992 (2002-05-01), None
patent: 09-268187 (1997-10-01), None
patent: 11-012265 (1999-01-01), None
patent: WO-91/15483 (1991-10-01), None
patent: WO-91-15483 (1991-10-01), None
patent: WO-95/03293 (1995-02-01), None
patent: WO-98/29403 (1998-07-01), None
Xiao et al., “Polyphenols based on isoflavones as inhibitors ofHelicobacter pyloriurease,” Bioorganic & Medicinal Chemistry, 2007, pp. 3703-3710, 15.
Stachulski et al., “Identification of Isoflavone Derivatives as Effective Anticryptosporidal Agents in Vitro and in Vivo,” J. Med. Chem., 2006, pp. 1450-1454, 49.
Vasselin et al., “Structural Studies on Bioactive Compounds. 40. Synthesis and Biological Properties of Fluoro-. Methoxyl-, and Amino-Substituted 3-Phenyl-4H-1-benzopyran-4-ones and a Comparison of Their Antitumor Activities with the Acitivies of Related 2-Phenylbenzothiazoles,” J. Med. Chem., 2006, pp. 3973-3981, 49.
Aggarwal et al., “Molecular targets of dietary agents for prevention and therapy of cancer,” Biochemical Pharmacology, 2006, pp. 1397-1421, 71.
Ren et al.,“Flavonoids: Promising Anticancer Agents,” Medical Research Reviews, 2003, pp. 519-534, vol. 23, No. 4.
Wang et al., “Genistein derivatives as selective estrogen receptor modulators: Sonochemical synthesis and in vivo anti-osteoporotic action,” Biochemical & Medicinal Chemistry, 2005, pp. 4880-4890, 13.
Ishimi et al., “Genistein, a Soybean Isoflavone, Affects Bone Marrow Lymphopoeisis and Prevents Bone Loss in Castrated Male Mice,” Bone, 2002, pp. 180-185, vol. 31, No. 1.
Morabito et al., “Effects of Genistein and Hormone-Replacement Therapy on Bone Loss in Early Postmenopausal Women: A Radomized Double-Blind Placebo-Controlled Study,” Journal of Bone and Mineral Research, 2002, pp. 1904-1912, vol. 17, No. 10.
Delcanale et al., “Novel Basic Isoflavones as Inhibitors of Bone Resorption,” Helvetica Chimica Acta, 2001, pp. 2417-2429, 84.
Wang et al., “Synthesis, antiproliferative, and antiplatelet activities of oxime- and methyloxime-containing flavone and isoflavone derivtives,” Bioorganic & Medicinal Chemistry, 2005, pp. 6045-6053, 13.
Gao et al., “Synthesis of Daidzin Analogues as Potential Agents for Alcohol Abuse,” Bioorganic & Medicinal Chemistry, 2003, pp. 4069-4081, 11.
Carmichael et al., “Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing,” Cancer Research, Feb. 15, 1987, pp. 936-942, 47.
Crowston et al., “Antimetabolite-Induced Apoptosis in Tenon's Capsule Fibroblasts,” IOVS, Feb. 1998, pp. 449-454, vol. 39, No. 2.
Gregory et al., “An Alizarin red-based assay of mineralization by adherent cells in culture:comparison with cetylpyridinum chloride extraction,” Analytical Biochemistry, 2004, pp. 77-84, 329.
Wu et al., “Flavones. 3. Synthesis, Biological Activities, and Conformational Analysis of Isoflavone Derivatives and Related Compounds,” J. Med. Chem., 1992, pp. 3519-3525, 35.
Kikuchi et al., “Brandisianins A-F, Isoflavonoids Isolated fromMillettia brandisianain a Screening Program for Death-Receptor Expression Enhancement Activity,” J. Nat. Prod., 2007, pp. 1910-1914, 70.
Alexandersen el al., “Ipriflavone in Treatment of Postmenopausal Osteoporosis,” JAMA, Mar. 21, 2001, pp. 1482-1488, vol. 285, No. 11.
Amari et al., “Synthesis, pharmacological evaluation, and structure-activity relationships of benzopyran derivatives with potent SERM activity,” Bioorganic & Medicinal Chemistry, 2004, pp. 3763-3782, 12.
Chang Je-Ken
Chen Yeh-Long
Fu Yin-Chih
Ho Mei-Ling
Tzeng Cherng-Chyi
Henley, III Raymond J
Kaosiung Medical University
Muncy Geissler Olds & Lowe, PLLC
LandOfFree
Isoflavone derivatives and pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoflavone derivatives and pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoflavone derivatives and pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4059016